Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Azithromycin is an antibiotic currently prescribed continuously in cystic fibrosis patients.
It was shown that this treatment taken every day or every week for 12 months, can improve the
respiratory state of patients. From the second year of treatment, it would appear there is
more profit to continue such treatment.
The main objective is to study the association between continuous use of azithromycin and
lung function measured by Forced expiratory volume in one second (FEV1), after two years of
treatment.